open access

Vol 2, No 2 (2011)
Review paper
Published online: 2011-07-15
Get Citation

The role of hematopoietic stem cell transplantation in the treatment of patients with plasma cell myeloma

Maria Adamczyk-Cioch
Hematologia 2011;2(2):131-139.

open access

Vol 2, No 2 (2011)
REVIEW ARTICLES
Published online: 2011-07-15

Abstract

Autologous hematopoietic stem cell transplantation (auto-HSCT) is still standard method in the frontline therapy of patients with plasma cell myeloma younger than 65 years. Novel agents, e.i. thalidomide, lenalidomide, bortezomib are incorporated into all phases of therapy, including: induction, conditioning, consolidation and maintenance. It results in higher preand posttransplantation complete remission (CR) rates and leads to a longer overall survival. Allogeneic transplantation (allo-HSCT) is still only an investigational procedure. Because of high transplantation-related mortality myeloablative allografting is replaced by reduced-intensity conditioning (RIC) after a debulky autologous transplantation.
Hematologia 2011; 2, 2: 131–139

Abstract

Autologous hematopoietic stem cell transplantation (auto-HSCT) is still standard method in the frontline therapy of patients with plasma cell myeloma younger than 65 years. Novel agents, e.i. thalidomide, lenalidomide, bortezomib are incorporated into all phases of therapy, including: induction, conditioning, consolidation and maintenance. It results in higher preand posttransplantation complete remission (CR) rates and leads to a longer overall survival. Allogeneic transplantation (allo-HSCT) is still only an investigational procedure. Because of high transplantation-related mortality myeloablative allografting is replaced by reduced-intensity conditioning (RIC) after a debulky autologous transplantation.
Hematologia 2011; 2, 2: 131–139
Get Citation

Keywords

plasma cell myeloma; hematopoietic stem cell transplantation; reduced intensity conditioning; thalidomide; lenalidomide; bortezomib

About this article
Title

The role of hematopoietic stem cell transplantation in the treatment of patients with plasma cell myeloma

Journal

Hematology in Clinical Practice

Issue

Vol 2, No 2 (2011)

Article type

Review paper

Pages

131-139

Published online

2011-07-15

Bibliographic record

Hematologia 2011;2(2):131-139.

Keywords

plasma cell myeloma
hematopoietic stem cell transplantation
reduced intensity conditioning
thalidomide
lenalidomide
bortezomib

Authors

Maria Adamczyk-Cioch

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.